secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001437749-25-028787
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera raises ~$17M in private placement with CorMedix; second closing tied to NEPHRO CRRT
--------------------------------------------------------------------------------

- Issued 25,036,360 shares at $0.55/share and pre-funded warrants for 5,845,455 shares; gross proceeds ~$17M.
- Second closing of ~$12M contingent on achieving primary endpoint in NEPHRO CRRT study and VWAP >= $0.6875.
- CorMedix gets board designation right if it holds >=25% of first-closing shares; 60-day exclusive negotiation right after positive NEPHRO CRRT results.
- Registration rights agreement requires Talphera to file resale registration statement within 15 days after each closing.
- Right of first negotiation terminates if NEPHRO CRRT study is terminated before primary endpoint or by Dec 31, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925028787/0001437749-25-028787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925028787/acrx20250909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-028787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer